Literature DB >> 30206098

Is a matched unrelated donor search needed for all allogeneic transplant candidates?

Stefan O Ciurea1, Maria Cecilia Borges Bittencourt1, Denái R Milton2, Kai Cao3, Piyanuch Kongtim1, Gabriela Rondon1, Julianne Chen1, Marina Konopleva4, Jorge M Ramos Perez1, Mohammed F El Shazly1, Majdi Aljadayeh1, Michele Alvarez1, Jin Im1, Gheath Al-Atrash1, Rohtesh Mehta1, Uday Popat1, Qaiser Bashir1, Betul Oran1, Chitra M Hosing1, Issa F Khouri1, Partow Kebriaei1, Richard E Champlin1.   

Abstract

Donor availability for allogeneic transplantation remains an important factor in determining outcomes of a successful transplant. We examined outcomes of 242 patients treated over 3 years who had a matched unrelated donor (MUD) search at our institution. One hundred sixty patients (66%) had a 10 of 10 MUD identified, and 85 (53%) proceeded to MUD transplantation. White patients and those with common haplotypes were more likely to have a MUD identified (odds ratio [OR], 7.4 [P < .0001]; OR, 41.6 [P < .0001]), and were more likely to proceed to transplantation with a MUD (OR, 11.2 [P < .0001]; OR, 85.1 [P = .002]). In addition, patients who were newly diagnosed/in remission at the time of MUD search had a higher probability of receiving a transplant (OR, 2.01 [P = .013]) and better progression-free survival (PFS; P < .0001). In multivariate analysis for patients who received a transplant, donor type did not influence PFS at 3 years, which was 40% for MUD and 57% for haploidentical transplants, respectively (hazard ratio, 1.2 [P = .50]). In conclusion, race, haplotype frequency, and disease status at the time of MUD search influence the probability of identifying a MUD and receiving a transplant. Patients with a low likelihood of receiving a MUD transplant may proceed to a haploidentical transplant as soon as indicated, as this approach does not appear to compromise transplant outcomes.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2018        PMID: 30206098      PMCID: PMC6134218          DOI: 10.1182/bloodadvances.2018021899

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  27 in total

Review 1.  National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants.

Authors:  Robert A Bray; Carolyn K Hurley; Naynesh R Kamani; Ann Woolfrey; Carlheinz Müller; Stephen Spellman; Michelle Setterholm; Dennis L Confer
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

2.  T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.

Authors:  Asad Bashey; Xu Zhang; Connie A Sizemore; Karen Manion; Stacey Brown; H Kent Holland; Lawrence E Morris; Scott R Solomon
Journal:  J Clin Oncol       Date:  2013-02-19       Impact factor: 44.544

3.  Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome.

Authors:  Neal Flomenberg; Lee Ann Baxter-Lowe; Dennis Confer; Marcelo Fernandez-Vina; Alexandra Filipovich; Mary Horowitz; Carolyn Hurley; Craig Kollman; Claudio Anasetti; Harriet Noreen; Ann Begovich; William Hildebrand; Effie Petersdorf; Barbara Schmeckpeper; Michelle Setterholm; Elizabeth Trachtenberg; Thomas Williams; Edmond Yunis; Daniel Weisdorf
Journal:  Blood       Date:  2004-06-10       Impact factor: 22.113

4.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Authors:  Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

5.  Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.

Authors:  Lauri M Burroughs; Paul V O'Donnell; Brenda M Sandmaier; Barry E Storer; Leo Luznik; Heather J Symons; Richard J Jones; Richard F Ambinder; Michael B Maris; Karl G Blume; Dietger W Niederwieser; Benedetto Bruno; Richard T Maziarz; Michael A Pulsipher; Finn B Petersen; Rainer Storb; Ephraim J Fuchs; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

6.  Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization.

Authors:  J Pidala; J Kim; M Schell; S J Lee; R Hillgruber; V Nye; E Ayala; M Alsina; B Betts; R Bookout; H F Fernandez; T Field; F L Locke; T Nishihori; J L Ochoa; L Perez; J Perkins; J Shapiro; C Tate; M Tomblyn; C Anasetti
Journal:  Bone Marrow Transplant       Date:  2012-08-06       Impact factor: 5.483

7.  Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.

Authors:  Anna Maria Raiola; Alida Dominietto; Carmen di Grazia; Teresa Lamparelli; Francesca Gualandi; Adalberto Ibatici; Stefania Bregante; Maria Teresa Van Lint; Riccardo Varaldo; Anna Ghiso; Marco Gobbi; Angelo Michele Carella; Alessio Signori; Federica Galaverna; Andrea Bacigalupo
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-05       Impact factor: 5.742

8.  Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Authors:  Abraham S Kanate; Alberto Mussetti; Mohamed A Kharfan-Dabaja; Kwang W Ahn; Alyssa DiGilio; Amer Beitinjaneh; Saurabh Chhabra; Timothy S Fenske; Cesar Freytes; Robert Peter Gale; Siddhartha Ganguly; Mark Hertzberg; Evgeny Klyuchnikov; Hillard M Lazarus; Richard Olsson; Miguel-Angel Perales; Andrew Rezvani; Marcie Riches; Ayman Saad; Shimon Slavin; Sonali M Smith; Anna Sureda; Jean Yared; Stefan Ciurea; Philippe Armand; Rachel Salit; Javier Bolaños-Meade; Mehdi Hamadani
Journal:  Blood       Date:  2015-12-15       Impact factor: 22.113

9.  Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually.

Authors:  J R Passweg; H Baldomero; P Bader; C Bonini; S Cesaro; P Dreger; R F Duarte; C Dufour; J Kuball; D Farge-Bancel; A Gennery; N Kröger; F Lanza; A Nagler; A Sureda; M Mohty
Journal:  Bone Marrow Transplant       Date:  2016-02-22       Impact factor: 5.483

10.  Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report.

Authors:  J R Passweg; H Baldomero; P Bader; C Bonini; R F Duarte; C Dufour; A Gennery; N Kröger; J Kuball; F Lanza; S Montoto; A Nagler; J A Snowden; J Styczynski; M Mohty
Journal:  Bone Marrow Transplant       Date:  2017-03-13       Impact factor: 5.483

View more
  10 in total

1.  A decision analysis comparing unrelated bone marrow transplantation and cord blood transplantation in patients with aggressive adult T-cell leukemia-lymphoma.

Authors:  Shigeo Fuji; Saiko Kurosawa; Yoshihiro Inamoto; Tatsunori Murata; Atae Utsunomiya; Kaoru Uchimaru; Satoshi Yamasaki; Yoshitaka Inoue; Yukiyoshi Moriuchi; Ilseung Choi; Masao Ogata; Michihiro Hidaka; Takuhiro Yamaguchi; Takahiro Fukuda
Journal:  Int J Hematol       Date:  2019-11-07       Impact factor: 2.490

2.  Is unrelated donor or haploidentical hematopoietic transplantation preferred for patients with acute myeloid leukemia in remission?

Authors:  Richard Champlin
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

3.  Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation.

Authors:  Jun Zou; Stefan O Ciurea; Piyanuch Kongtim; Min Yi; Yudith Carmazzi; Gabriela Rondon; Samer Srour; David Partlow; Richard E Champlin; Kai Cao
Journal:  Blood Adv       Date:  2020-08-11

4.  Outcomes of Related and Unrelated Donor Searches Among Patients with Primary Immunodeficiency Diseases Referred for Allogeneic Hematopoietic Cell Transplantation.

Authors:  Mary Joseph Acevedo; Jennifer S Wilder; Sharon Adams; Joie Davis; Corin Kelly; Dianne Hilligoss; Ellen Carroll; Bazetta Blacklock-Schuver; Kristen Cole; Elizabeth M Kang; Amy P Hsu; Christopher G Kanakry; Dimana Dimitrova; Jennifer A Kanakry
Journal:  Biol Blood Marrow Transplant       Date:  2019-04-12       Impact factor: 5.742

Review 5.  Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors.

Authors:  Andreas Hochhaus; Massimo Breccia; Giuseppe Saglio; Valentín García-Gutiérrez; Delphine Réa; Jeroen Janssen; Jane Apperley
Journal:  Leukemia       Date:  2020-05-04       Impact factor: 11.528

6.  Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia.

Authors:  Dalma Deak; Cristina Pop; Alina-Andreea Zimta; Ancuta Jurj; Alexandra Ghiaur; Sergiu Pasca; Patric Teodorescu; Angela Dascalescu; Ion Antohe; Bogdan Ionescu; Catalin Constantinescu; Anca Onaciu; Raluca Munteanu; Ioana Berindan-Neagoe; Bobe Petrushev; Cristina Turcas; Sabina Iluta; Cristina Selicean; Mihnea Zdrenghea; Alina Tanase; Catalin Danaila; Anca Colita; Andrei Colita; Delia Dima; Daniel Coriu; Hermann Einsele; Ciprian Tomuleasa
Journal:  Front Immunol       Date:  2019-12-20       Impact factor: 7.561

Review 7.  Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia.

Authors:  Servais Sophie; Beguin Yves; Baron Frédéric
Journal:  Stem Cells Transl Med       Date:  2022-05-27       Impact factor: 7.655

8.  Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age.

Authors:  Colin Flannelly; Bryan E-Xin Tan; Jian Liang Tan; Colin M McHugh; Chandrika Sanapala; Tara Lagu; Jane L Liesveld; Omar Aljitawi; Michael W Becker; Jason H Mendler; Heidi D Klepin; Wendy Stock; Tanya M Wildes; Andrew Artz; Navneet S Majhail; Kah Poh Loh
Journal:  Biol Blood Marrow Transplant       Date:  2020-09-20       Impact factor: 5.609

9.  ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia.

Authors:  Denis Claude Roy; Irwin Walker; Johan Maertens; Philippe Lewalle; Eduardo Olavarria; Dominik Selleslag; Sylvie Lachance; Marc Buyse; Kun Wang; Jeroen Rovers; Irene Santi; Halvard Bonig; Andrew Sandler; Jurjen Velthuis; Stephan Mielke
Journal:  Leukemia       Date:  2020-02-11       Impact factor: 11.528

10.  Outcome of Patients Treated with Hematopoietic Stem Cell Transplantation: Results from A Single Center.

Authors:  Gholamreza Bahoush
Journal:  Asia Pac J Oncol Nurs       Date:  2021-01-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.